New Therapeutics for Heart Failure: Focusing on cGMP Signaling
Issued Date
2023-08-16
Resource Type
eISSN
14220067
Scopus ID
2-s2.0-85168717834
Pubmed ID
37629047
Journal Title
International journal of molecular sciences
Volume
24
Issue
16
Rights Holder(s)
SCOPUS
Bibliographic Citation
International journal of molecular sciences Vol.24 No.16 (2023)
Suggested Citation
Mangmool S., Duangrat R., Parichatikanond W., Kurose H. New Therapeutics for Heart Failure: Focusing on cGMP Signaling. International journal of molecular sciences Vol.24 No.16 (2023). doi:10.3390/ijms241612866 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/89153
Title
New Therapeutics for Heart Failure: Focusing on cGMP Signaling
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Current drugs for treating heart failure (HF), for example, angiotensin II receptor blockers and β-blockers, possess specific target molecules involved in the regulation of the cardiac circulatory system. However, most clinically approved drugs are effective in the treatment of HF with reduced ejection fraction (HFrEF). Novel drug classes, including angiotensin receptor blocker/neprilysin inhibitor (ARNI), sodium-glucose co-transporter-2 (SGLT2) inhibitor, hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker, soluble guanylyl cyclase (sGC) stimulator/activator, and cardiac myosin activator, have recently been introduced for HF intervention based on their proposed novel mechanisms. SGLT2 inhibitors have been shown to be effective not only for HFrEF but also for HF with preserved ejection fraction (HFpEF). In the myocardium, excess cyclic adenosine monophosphate (cAMP) stimulation has detrimental effects on HFrEF, whereas cyclic guanosine monophosphate (cGMP) signaling inhibits cAMP-mediated responses. Thus, molecules participating in cGMP signaling are promising targets of novel drugs for HF. In this review, we summarize molecular pathways of cGMP signaling and clinical trials of emerging drug classes targeting cGMP signaling in the treatment of HF.